Georgiou, George Ph.D.

Professor, Cockrell Family Regent’s Chair in Engineering #9

photo of George Georgiou
Office: CPE 4.410 Mailing Address:
Phone: (512) 471-6975 The University of Texas at Austin
Fax:  (512) 471-7060 McKetta Department of Chemical Engineering
Email: gg@che.utexas.edu 200 E Dean Keeton St. Stop C0400
UT Mail: C0400 Austin, TX 78712-1589

Research Areas: Biotechnology

Research Website

Research Presentation for Prospective Graduate Students

Educational Qualifications

Ph.D., Chemical Engineering, Cornell University (1987)
M.S., Chemical Engineering, Cornell University (1983)
B.Sc., Chemical Engineering, University of Manchester Institute of Science and Technology (UMIST), England (1981)

Courses Taught

CHE 339      Introduction to Biochemical Engineering
CHE 317      Chemical Engineering Analysis and Calculations
CHE 322      Thermodynamics
CHE 264      Chemical Engineering Process Laboratory
CHE 395F    Advanced Biochemical Engineering
CHE 384N    Fermentation Technology
CHE 384K    Biomolecular Recognition

Research

Since 2009 the Georgiou Lab has been focused on the discovery and development of protein therapeutics and on the analysis of adaptive immune responses.   Current projects include:

  • Engineering and preclinical/clinical development of human enzyme therapeutics for cancer treatment
  • Development of methods for the molecular-level understanding of antibody responses to immune challenge
  • Analysis of the antibody repertoire elicited by viral infection (e.g. HIV-1) and vaccination to aid the development of more efficient vaccines
  • Engineering of antibody therapeutics displaying enhanced ability to recruit cytotoxic leukocytes and blood proteins (complement) for the effective clearance of pathogens

Earlier work by the Georgiou Lab had focused on redox homeostasis and protein biogenesis in bacteria and on the development of platform technologies for protein expression and engineering. These studies led to a number of mechanistic advances and to new technologies that are being used commercially for therapeutic protein manufacturing and protein engineering.  Dr. Georgiou is co-inventor of 29 issued and 46 pending US patents. Notably, 16 different technology suites (comprising either one or multiple patents) have been licensed to majorepharmaceutical and biotechnology companies

Awards & Honors

Elected to the Institute of Medicine of the National Academies (2010)
Named as one of “100 Eminent Chemical Engineers of the Modern Era,” American Institute of Chemical Engineering (2008)
AMGEN Award in Biochemical Engineering (2007)
National Academy of Engineering (2005)
Fellow of the American Academy of Microbiology (2004)
Fellow of the American Association for the Advancement of Science (2004)
Professional Progress Award for Outstanding Progress in Chemical Engineering, American Institute of Chemical Engineering (2003)
Marvin J. Johnson Award in Microbial and Biochemical Technology, American Chemical Society (2003)
Fellow, American Institute for Medical and Biological Engineering (1996)
E. Bergman Award, US-Israel Science Foundation (1995)

Selected Publications

  • Doria-Rose, N.A… Georgiou, G.… P.D. Kwong and J.R. Mascola, “Developmental Pathway for Potent V1V2-Directed HIV-1-Neutralizing Antibodies,”  Nature (in press, 2014)
  • Georgiou G., Ippolito, G., Beuasang, G., Busse, C.E., Wardemann, H. and S.R. Quake, “The Promise and Challenge of High-throughput Sequencing of the Antibody Repertoire,” Nature Biotechnol. 32:158-68 (2014)
  • Quandt, E.M., Deatherage, D.E., Ellington, A.D., Georgiou, G. and J. E. Barrick, “Recursive Genome-Wide Recombination and Sequencing Reveals a Key Refinement Step in the Evolution of a Metabolic Innovation in E. coli,”  Proc. Natl. Acad. Sci. USA 111:2217-22 (2014)
  • Lavinder, J., Wine, Y., Giesecke, C., Ippolito, G.C., Horton, A.P., Hoi, K.-H., DeKosky, B.J., Ellington, A.D., Dörner, T., Marcotte, E.M., Boutz, D.R. and G. Georgiou,  “Dynamics, Functionality and Discordance of the Human Serum Antibody and BCR Repertoires Following Immunization” Proc. Natl. Acad. Sci. USA 111:2259-64(2014)
  • Li, Y., Gebhard, M.C., Qing, L., Georgiou, G. and B.L. Iverson, B.L.,  “Engineering of Novel TEV Protease Variants by Yeast ER Sequestration Screening (YESS) of Combinatorial Libraries” Proc. Natl. Acad. Sci. USA 110:7229-34 (2013)
  • DeKosky, B.J., Ippolito,G.C., Deschner,R.P., Lavinder,J.J., Rawlings,M.P., Varadarajan,N., Wine, Y., Giesecke,C., Dörner,T., Andrews, S.F., Wilson,P.C., Hunicke-Smith, S.P., Wilson, C.P., Ellington, A.D. and G. Georgiou, “High Throughput Determination of the Antibody VH:VL Paired Repertoires,” Nature Biotechnol. 31:166-69(2013)
  • Wine, Y., Boutz, D.R., Lavinder, J.J., Horton, A., Miklos, A.E., Hughes, R.A., Jung, S.T, Murrin E.M., Ellington, A.D., Marcotte, E.M. and G. Georgiou,  “Molecular Deconvolution of the Monoclonal Antibodies that Comprise the Polyclonal Serum Response,” Proc. Natl. Acad. Sci. USA 110: 2993-8(2013) PMID: 23382245
  • Jung, S. T., Kelton, W., Kang, T. H.; Ng, D., Anderssen, J. T.; Sandlie, I., Sarkar, C., G. Georgiou, “Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity” ACS Chem. Bio. 8:368-75 (2013)
  • Stone, E.M., Paley, O., Hu, J., Ekerdt, B.; Cheung, N.-K. and G. Georgiou, “De novo Engineering of a Human Methionine-γ-Lyase for Systemic L-Met Depletion Cancer Therapy,” ACS Chem. Bio. 7:1822-9 (2012)